Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin glycinate - Laboratorios Silanes

Next Previous
Drug Profile

Metformin glycinate - Laboratorios Silanes

Alternative Names: DDMET-01; Metformin glycinate

Latest Information Update: 28 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratorios Silanes
  • Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III SARS-CoV-2 acute respiratory disease; Type 2 diabetes mellitus

Most Recent Events

  • 28 Nov 2022 Metformin glycinate is still in the phase III DMMETCOV19-2 trial for SARS-COV-2 acute respiratory disease in Mexico (PO) (NCT04625985)
  • 08 Apr 2021 Laboratorios Silanes withdraws the phase II DMMETCOV19 trial prior to enrolment for Type 2 diabetes mellitus, Metabolic syndrome and SARS-COV-2 acute respiratory disease in Mexico (PO) due to company administrative decision (NCT04626089)
  • 18 Mar 2021 Laboratorios Silanes completes the phase III DMMETCOV19-2 trial in SARS-COV-2 acute respiratory disease in Mexico (PO) (NCT04625985)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top